21
May 2021 May 2021
May 21 2021
NSW Health moves to Green Alert
Effective immediately, NSW Health services will move from an amber alert (moderate transmission) to a green alert (low transmission).
07
September 2023 Sep 2023
Posted September 07, 2023
COVID-19 vaccines continue to be effective in reducing the risk of severe illness and death. This is particularly important for older adults and those with risk factors for severe disease (1).
The Australian Technical Advisory Group on Immunisation (ATAGI) has released updated recommendations regarding an additional 2023 COVID-19 dose for the highest-risk population groups. These recommendations add to the previous ATAGI COVID-19 vaccine booster advice published in February 2023 (1).
ATAGI recommends that all adults aged 75 years and over should receive an additional 2023 COVID-19 vaccine dose if 6 months have passed since their last dose. (1)
ATAGI also advises that the following groups should consider an additional 2023 COVID-19 vaccine dose if 6 months have passed since their last dose, after discussion with their healthcare provider:
Within the above groups, an additional 2023 COVID-19 vaccine dose is likely to be of greatest benefit for people who:
ATAGI continues to encourage all adults who were recommended to have a COVID-19 vaccine dose in February 2023, and who have not yet had one, to receive a vaccine dose as soon as possible (1).
What about younger patients?
For younger people or older adults without severe immunocompromise who have already had a dose in 2023, no further doses are currently recommended (1). Their risk of severe illness is low if they have already been vaccinated, and particularly if they have previously been infected with Covid (1, 2).
What vaccines are recommended?
Bivalent Omicron-based mRNA COVID-19 vaccines continue to be preferred for all doses in people aged ≥ 12 years (1).
ATAGI notes that XBB.1.5-based vaccines have been developed, but these are not yet approved for use by any country and updates will be provided as information is available (1).
Subscribe to our mailing list to get all the latest news updates delivered to your inbox.